IGF::OT::IGFEMMES NEIS-V

基本信息

批准号：
9591728
负责人：
KERI HAMMEL
金额：
$ 671.8万
依托单位：
THE EMMES COMPANY, LLC
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-11-01 至 2017-10-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9591728
关键词：
Acquired Immunodeficiency Syndrome Adrenal Cortex Hormones Age related macular degeneration Antigens Area Analyses Behcet Syndrome Case-Control Studies Cell Line Ciliary Neurotrophic Factor Clinical Clinical Research Clinical Trials Collection Coloboma Cone Contractor Contracts Cyst DNA Repository Dark Adaptation Data Analyses Databases Diabetic Retinopathy Diagnosis Disease Early treatment Economics Electrooculogram Enrollment Epidemiology Epigenetic Process Evaluation Evaluation Studies Extramural Activities Eye Eye diseases Family Follow-Up Studies Gene Transfer Generations Genes Genetic Genetic Markers Genetic study Genotype Healthcare Image Immune response Immunogenetics Immunology Inflammation Mediators Inflammatory Inherited Interferon gamma 1b Intramural Research Investigation Laboratories Mediating Medicare Microglia Minocycline Molecular Molecular Genetics National Eye Institute Natural History Oral Outcome Outcomes Research Participant Pathogenesis Patient Monitoring Patients Phase Phase I/II Trial Phenotype Pilot Projects Platelet-Derived Growth Factor Proteome Quality-of-Life Assessment Randomized Clinical Trials Research Retinal Retinal Diseases Retinal Vein Occlusion Retinitis Pigmentosa Somatic Cell Specific qualifier value Syndrome Telangiectasis Toxic effect Type 7 Spinocerebellar Ataxia Uveitis Vertebrate Photoreceptors Vision Vision Disorders Visual Motor Coordinations Von Hippel-Lindau Syndrome Work X-Linked Retinoschisis active method adaptive optics age related biobank central retinal vein occlusion cost effectiveness data management design disorder of macula of retina exome follow-up gene therapy genome sequencing geographic atrophy induced pluripotent stem cell inhibitor/antagonist macula macular edema microbiome patient expectation patient safety preclinical study ranibizumab repository screening whole genome

项目摘要

This contract is designed to attain extramural support for developing, designing, interpreting, and evaluating clinical trials, epidemiologic and natural history studies. In addition, it will provide for outcomes research involving eye diseases and visual disorders and some preclinical studies. The focus shall be on the design of studies and the collection, analysis, and interpretation of data emanating from these studies, as well as support, and monitoring patient safety and follow-up. Contractor shall also provide analytical and data management support, as described in the work statement, for specified clinical research data bases, cost-effectiveness and economic analyses, quality of life assessment and outcomes research. This will include, but not be limited to, the following areas: analysis of Medicare and other health care databases; evaluation of existing NEI databases such as, centralized NEI Intramural Research database, the Eye Disease Case Control Study, Early Treatment Diabetic Retinopathy Study, Framingham Eye Study, and intramural AIDS and uveitis databases.

该合同旨在获得开发，设计，解释和评估临床试验，流行病学和自然史研究的壁外支持。此外，它将提供涉及眼部疾病和视觉疾病以及一些临床前研究的结果研究。重点应放在研究的设计以及从这些研究中发出的数据的收集，分析和解释，以及支持以及监测患者的安全和随访。正如工作声明中所述，承包商还应为特定的临床研究数据库，成本效益和经济分析，生活质量评估和成果研究提供分析和数据管理支持。这将包括但不限于以下领域：Medicare和其他医疗保健数据库的分析；评估现有的NEI数据库，例如集中式NEI NEI研究数据库，眼病病例对照研究，早期治疗糖尿病性视网膜病变研究，Framingham Eye研究以及壁内艾滋病和葡萄膜炎数据库。